Raymond James Financial
LEXX icon

Raymond James Financial’s Lexaria Bioscience LEXX Stock Holding History

Raymond James Financial’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-61,250
Closed -$105K – 7035
2025
Q1 		$105K Buy
61,250
+610
+1% +$1.03K ﹤0.01% 4540
2024
Q4 		$127K Buy
+60,640
New +$149K ﹤0.01% 4492

Other funds holding LEXX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial's LEXX Position: Q2 2025 in Review

Raymond James Financial sold out of Lexaria Bioscience (LEXX) in Q2 2025, closing a stake of 61,250 shares — an estimated $105K sold.

Raymond James Financial first reported a position in LEXX in Q4 2024 and held it in 2 quarters. The position peaked at $127K in Q4 2024. 21 funds tracked by Wall St. Rank hold LEXX as of Q2 2025.

  • Raymond James Financial reported no remaining Lexaria Bioscience position as of Q2 2025 after selling out during the quarter.
  • Raymond James Financial sold 61,250 Lexaria Bioscience shares in Q2 2025, an estimated $105K.
  • Raymond James Financial first reported a position in Lexaria Bioscience in Q4 2024 and held it in 2 quarters.
  • Raymond James Financial's Lexaria Bioscience position peaked at $127K in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2025.

Based on Raymond James Financial's 13F filing for Q2 2025, filed 14 Aug 2025.